<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695771</url>
  </required_header>
  <id_info>
    <org_study_id>Version 4 Date: 04.08.2016</org_study_id>
    <nct_id>NCT02695771</nct_id>
  </id_info>
  <brief_title>The Bladder Instillation Comparison Study</brief_title>
  <acronym>BIC</acronym>
  <official_title>A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single
      intraoperative instillation in preventing recurrence of bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare standard of care treatment for patients with non-muscle invasive
      bladder cancer (NMIBC). Patients will be randomized to one of three arms, Mitomycin C,
      Gemcitabine or no additional treatment immediately following TURBT in the operating suite.
      All treatment, surgical procedures and follow up care will be conducted according to standard
      of care treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy will be measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study treatment, graded according to NCI CTCAE Version 4.03</measure>
    <time_frame>Two years</time_frame>
    <description>To compare the efficacy of Mitomycin C 40 mg in 40 mL of 0.9% sodium chloride intravesicular vs. Gemcitabine 2 grams in 100 mL of 0.9% sodium chloride intravesicular vs. no adjuvant treatment as a single intraoperative instillation immediately after TURBT in preventing NMIBC recurrence. Efficacy will be measured by the number of patients with Grade 3 through Grade 5 AdverseEvents that are related to study treatment, graded according to NCI CTCAE Version 4.03.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of dystrophic calcification or bladder calculi</measure>
    <time_frame>Two years</time_frame>
    <description>The secondary endpoint for this study will be the incidence of dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Urinary Bladder Neoplasms</condition>
  <arm_group>
    <arm_group_label>Mitomycin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitomycin C 40 mg in 40 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 2 grams in 100 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to this arm will receive no intervention intravesicular immediately following TURBT one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Cancer chemotherapeutic agent</description>
    <arm_group_label>Mitomycin C</arm_group_label>
    <other_name>Mutamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Cancer chemotherapeutic agent</description>
    <arm_group_label>Gemcitabine</arm_group_label>
    <other_name>Gemzar, Novaplus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. sign an informed consent for the study

          2. be scheduled for a TURBT for suspected non-muscle invasive bladder tumor.

        Exclusion Criteria:

          1. patients unable to consent for themselves

          2. individuals under 18 years old

          3. pregnant women

          4. prisoners

          5. patients with known allergy or intolerance to the mitomycin C or Gemcitabine

          6. any other sound medical, psychiatric and/or social reason as determined by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E Humphrey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan M Engerman, BSN</last_name>
    <phone>616-267-8406</phone>
    <email>susan.engerman@spectrumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Carlon, RN</last_name>
    <phone>616-267-8406</phone>
    <email>pamela.carlon@spectrumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spectrum Health Medical Group-Division of Urology-LHCP</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan M Engerman, BSN</last_name>
      <phone>616-267-8406</phone>
      <email>susan.engerman@spectrumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Carlon, RN</last_name>
      <phone>616-267-8406</phone>
      <email>pamela.carlon@spectrumhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Medical Group-Division of Urology</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan M Engerman, BSN</last_name>
      <phone>616-267-8406</phone>
      <email>susan.engerman@spectrumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Carlon, RN</last_name>
      <phone>616-267-8406</phone>
      <email>pamela.carlon@spectrumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Richard J Kahnoski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian R Lane, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip T Hoekstra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan T Bolthouse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hector Pimentel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher M Brede, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John E Humphrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants P.C.</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan M Engerman, BSN</last_name>
      <phone>616-267-8406</phone>
      <email>susan.engerman@spectrumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Carlon, RN</last_name>
      <phone>616-267-8406</phone>
      <email>pamela.carlon@spectrumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>John G Anema, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon M Curry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phillip G Wise, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weijers Y, Arentsen HC, Arends TJ, Witjes JA. Management of low-risk and intermediate-risk non-muscle-invasive bladder carcinoma. Hematol Oncol Clin North Am. 2015 Apr;29(2):219-25, vii. doi: 10.1016/j.hoc.2014.11.001. Review.</citation>
    <PMID>25836930</PMID>
  </reference>
  <reference>
    <citation>Pagano MJ, Badalato G, McKiernan JM. Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited. Curr Urol Rep. 2014 Nov;15(11):450. doi: 10.1007/s11934-014-0450-1. Review.</citation>
    <PMID>25234184</PMID>
  </reference>
  <reference>
    <citation>Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol. 2015 Nov;68(5):868-79. doi: 10.1016/j.eururo.2015.06.044. Epub 2015 Jul 16.</citation>
    <PMID>26188393</PMID>
  </reference>
  <reference>
    <citation>Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004 Jun;171(6 Pt 1):2186-90, quiz 2435.</citation>
    <PMID>15126782</PMID>
  </reference>
  <reference>
    <citation>Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ; International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001 Apr 18;93(8):597-604.</citation>
    <PMID>11309436</PMID>
  </reference>
  <reference>
    <citation>Montgomery JS, Miller DC, Weizer AZ. Quality indicators in the management of bladder cancer. J Natl Compr Canc Netw. 2013 Apr 1;11(4):492-500. Review.</citation>
    <PMID>23584349</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spectrum Health Hospitals</investigator_affiliation>
    <investigator_full_name>John E. Humphrey</investigator_full_name>
    <investigator_title>Urologist</investigator_title>
  </responsible_party>
  <keyword>bladder tumors</keyword>
  <keyword>urinary tumors</keyword>
  <keyword>non-muscle invasive bladder tumors</keyword>
  <keyword>NMIBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

